Sorry, but nothing matched your search terms. Please try again with some different keywords.
Nothing Found
Archive
- 2023
- 2022
- Scandinavian Biopharma donates mosquito nets to orphanages in Benin – a gift that saves lives
- New ETVAX® data was presented during VASE, an international gathering dedicated to develop Shigella and ETEC vaccines
- Scandinavian Biopharma welcomes Johan Jarmander to the position as Drug Substance Specialist Manufacturing & Development
- Scandinavian Biopharma enters into a commercial collaboration with Novavax in Sweden
- Scandinavian Biopharma has successfully completed the enrolment of their large Phase IIb trial in The Gambia
- We continue to expand and welcome Marja Held as Senior Regulatory Affairs Manager
- Scandinavian Biopharma welcomes Anna Sumic to the position as Drug Substance and Drug Product Manufacturing Specialist
- We are looking for a Clinical Project Manager
- 10/10 Marks A Day to Bring Awareness to One of The Rarest Bleeding Disorders
- Read about our ETEC Vaccine development in the Annual Report from EDCTP
- Scandinavian Biopharma announces marketing and distribution agreement with Emergent to relaunch the oral typhoid vaccine (Ty21a) in Germany
- Scandinavian Biopharma extends its agreement with USAMMDA and obtains additional financial support
- Scandinavian Biopharma recruits Agneta Lissmats as Senior Director Biostatistics
- Scandinavian Biopharma made important progress in research, set a new sales record and strengthened the organization in 2021
- Scandinavian Biopharma welcomes Sara Grahm to the position as Director of Manufacturing
- Scandinavian Biopharma welcomes Maria Edlund to the position as Drug Product Manufacturing Specialist
- Scandinavian Biopharma continuous the tradition of donating food to orphanages in Grand Popo, Benin!
- Scandinavian Biopharma’s expansion requires expanded premises
- Scandinavian Biopharma strengthens its vaccine portfolio in the field of diarrhoeal disease by in-licencing a Campylobacter vaccine technology from Canadian company, VaxAlta Inc.
- 2021
- An improved formulation of Scandinavian Bioharmas ETEC vaccine candidate is currently being tested in an immunogenicity bridging study
- We welcome Aino Råberg as Drug Substance Lead Manufacturing at Scandinavian Biopharma
- New ETVAX® data will be presented during VASE, a conference designed to spark innovation and accelerate the momentum for research and development on enteric vaccines
- We welcome Camilla Jidling – our new QA Manager
- Scandinavian Biopharma is growing and we now welcome Maria Fernanda Ehrman
- Welcome Günes Uysal
- We are delighted to be highlighted in the science and innovation magazine, EU Research magazine, from the European Union
- We are proud to be part of the fight against malaria through our collaboration with Care Plus®
- Scandinavian Biopharma shows strong financial results for the pandemic year 2020
- Scandinavian Biopharma is present at Nordic Life Science Days
- Susanne Ellfors-Zetterlund new Chief Medical Officer (CMO) at Scandinavian Biopharma
- The first children have been vaccinated in Scandinavian Biopharma’s large Phase IIb study in The Gambia
- We welcome Tomas Danielsson as Senior Project Manager Manufacturing at Scandinavian Biopharma
- Telia has chosen to highlight us in their promotion campaign
- Scandinavian Biopharma’s clinical phase IIb study in Benin has become a documentary
- 2020
- We continue to expand and welcome Catharina Forzelius as our Program Director
- Scandinavian Biopharma recruits Christin Hindrika Strid as Clinical Operations Manager
- We continue to expand and welcome Åsa Dahlbäck as VP Regulatory Affairs
- EY Announces Scandinavian Biopharma CEO and founder, Björn Sjöstrand, as a Stockholm finalist for the prestigious ‘Entrepreneur Of The Year’ award
- Scandinavian Biopharma provides seasonal gifts already during the beginning of November because of the pandemic
- The World Health Organization concludes that ETEC remains a priority pathogen and is encouraged by our preliminary phase 2B results from Benin
- Scandinavian Biopharma enters into Agreement with USAMRAA to facilitate the development of the oral vaccine ETVAX® against travellers’ diarrhoea
- Scandinavian Biopharma continues to expand and welcomes Erika Söderström as Key Account Manager
- Scandinavian Biopharma has successfully completed the enrolment of the clinical Phase 1 trial in Zambia
- We continue to expand and welcome Robert Lindberg
- Scandinavian Biopharma expand their portfolio with Coagadex® – the first and only tailormade treatment for the rare bleeding disorder ‘factor X deficiency’
- Promising preliminary findings from a Phase 2b study of the oral vaccine ETVAX® against travelers’ diarrhea in Finnish travelers to Benin, West Africa
- Scandinavian Biopharma recruits Anna Hill as Clinical Operations Manager
- The science is clear – let us highlight and support ‘World Immunization Week’
- Scandinavian Biopharma is once again looking back on a very successful business year
- Welcome Morgan Hjorth
- Scandinavian Biopharma secures €10.6 million from EDCTP for a Phase III trial of ETVAX® in children in low- and middle-income countries
- Scandinavian Biopharma expands its Nordic vaccine business with the oral typhoid vaccine Vivotif®
- 2019
- Christine Källén joins Scandinavian Biopharma as our new VP Quality Assurance
- Scandinavian Biopharma Wishes Happy Holidays by donating food, medicines and mattresses to several orphanages in Benin!
- Scandinavian Biopharma reports successful results of the oral, inactivated ETEC vaccine candidate ETVAX® against enterotoxigenic E. coli diarrhoea in a placebo-controlled phase I/II study in infants and children from 6 months to 5 years of age in Bangladesh
- The successful immunogenicity and safety results of ETVAX® are presented at Vaccines for Enteric Diseases (VED) Oct 16-18 in Lausanne, Switzerland
- Scandinavian Biopharma awarded and qualified “Gazelle Company” by Dagens Industri
- We are one of the Biotech Company of the Year finalists at the 2019 European Lifestars Awards!
- We have successfully completed the enrolment of the first cohort including 40 adults in our study in Zambia
- Scandinavian Biopharma is launching an updated brand identity
- Scandinavian Biopharma announces great progress in the development of ETVAX® as well as a strong organic growth for the distribution business
- Scandinavian Biopharma welcomes Dilek Merdol as new head of Quality Control (QC)
- Scandinavian Biopharma announces the last follow up visit in the phase IIB clinical trial with ETVAX® in Finnish travellers to Benin
- Scandinavian Biopharma officially starts their late phase development program in Africa funded by EDCTP
- Scandinavian Biopharma recruits Madelene Franzén as Accounting Manager
- Scandinavian Biopharma has been awarded 7.4 million EUR from the EU for clinical trials of ETVAX® – a unique and newly developed vaccine against diarrheal disease
- 2018
- Scandinavian Biopharma Wishes Happy Holidays by donating food to an orphanage in Grand Popo, Benin!
- Tomas Åslund joins Scandinavian Biopharma as VP Manufacturing
- The Entrepreneur of the Year in Solna
- Our collaboration partner, Jan Holmgren, is receiving the world’s biggest award in the field of global health
- Scandinavian Biopharma awarded the Swedish national tender for the TdaP booster vaccine
- We are proud to be “2018 Distributor of the year”
- Sweden’s ambassador Annika Thunborg attended the VASE conference in Mexico City
- We want to raise awareness
- New ETVAX® data will be presented during Vaccines Against Shigella and ETEC (VASE) conference in Mexico
- Kyoko Misawa joins Scandinavian Biopharma as Clinical study manager
- Scandinavian Biopharma is once again looking back on a highly successful business year
- Our Phase IIB study on the BBC news!
- Meet Scandinavian Biopharma at Northern European Conference on Travel Medicine (NECTM 7) in Stockholm
- Scandinavian Biopharma gets support by the County Administrative Board in Stockholm
- Guest editor for Stockholm Science City on Instagram
- Our vaccine project on PATH´s DefeatDD Blog
- Welcome to Scandinavian Biopharma,
- 2017
- Charlotte Flodin joins Scandinavian Biopharma as VP Quality Assurance
- Jonas Bengtsson joins Scandinavian Biopharma as VP Business Development and International Sales
- New ETVAX® data will be presented during Vaccines for Enteric Diseases (VED) conference
- We look forward seeing you at Nordic Life Science Days
- Scandinavian Biopharma continues to grow – 2016 was another successful year
- Our collaboration partner, Jan Holmgren, is awarded the world’s greatest vaccine prize
- Scandinavian Biopharma enters into an exclusive agreement with Flynn Pharma for ViperaTAb
- Scandinavian Biopharma is expanding by hiring a PhD in cell- and molecular biology
- All 450 participants starting from adults down to 6 months young infants are enrolled in our study in Bangladesh
- 2016
- 2015
- Our ETEC-story is told in ”European Biotechnology”
- ETVAX® was presented at ASTMH in Philadelphia
- Scandinavian Biopharma expands its product portfolio with an immunosuppressive drug
- Scandinavian Biopharma announces first patient vaccinated in the age-descending study in Bangladesh
- ETVAX® was presented as the lead candidate at CISTM14
- Scandinavian Biopharma and PATH sign amendment to collaborative agreement to develop a vaccine against diarrhoeal disease
- 2014
- Impressive results in new Vaccine publication
- Mapping the spread of diarrheal bacteria supports the design of our new vaccine
- Our story is told in a new editorial book
- Scandinavian Biopharma receives 4.5 MSEK in funding from Vinnova
- Etvax® is now a registered trademark
- Scandinavian Biopharma is expanding by hiring a pharmacist, PhD in microbiology
- Scandinavian Biopharma – A Fast Growing Swedish biotech company
- 2013
- Scandinavian Biopharma and PATH sign collaborative development agreement after successful Phase I study of a novel vaccine candidate against diarrheal disease.
- Phase I results will be presented at the International Conference on Mucosal Vaccines, Adjuvants & Delivery, in Copenhagen
- Scandinavian Biopharma announces successful results in placebo-controlled Phase I study of an oral, inactivated vaccine against diarrhea for travelers and children in developing countries
- Preclinical studies of the new oral Traveler’s diarrhea vaccine shows that it is safe and immunogenic
- Scandinavian Biopharma through its subsidiary ETVAX continues clinical development
- 2012
